Non-invasive Screening of Fetal Trisomy 21 by Digital PCR

Status Terminated

Clinical Trial Summary

In France, as in many countries of the world, trisomy 21 or Down syndrome (DS) is the subject of an antenatal screening based on a risk calculation (R) including the assay of biochemical markers in the maternal blood, and the measurement of a fetal ultrasound parameter (nuchal translucency). In the population of pregnant women said to be at high risk (R> 1/250), confirmation of the diagnosis of DS is made by invasive sampling (trophoblast biopsy or amniocentesis), which allows the establishment of fetal karyotype. In addition to limited sensitivity (80 to 85% depending on the techniques), this screening is an anxiety factor (8% false positives), and miscarriages of euploid fetuses (normal karyotype) in 1% of cases (procedures invasive). The plasma of a pregnant woman contains a mixture of free DNA of maternal (90%) and fetal origin (cffDNA for cell free fetal DNA) (about 10%, but this proportion increases in cases of fetal trisomy 21. The proportion of cffDNA is sufficient to qualitatively and quantitatively study specific genetic markers of a pair of chromosomes. It is therefore possible to evaluate the quantity of markers chromosome of interest relative to a reference chromosome marker, and to calculate a marker / marker ratio of interest, theoretically identical for all autosomes (chromosomes 1 to 22) during euploid pregnancy. In case of fetal aneuploidy (for example, trisomy 21), this ratio is unbalanced for the chromosomal pair involved. Advances in technology, such as high-throughput mass sequencing (MPS) and digital PCR (dPCR), now make it possible to consider the diagnosis of fetal maternal DS through the study of cffDNA. Several teams have already published on this subject with the MPS technique, applied directly to free DNA from maternal plasma, or after a cffDNA isolation step. This involves sequencing the DNA fragments present in the sample and placing them back on their original chromosome. In case of trisomy 21 fetal, one seeks to put in evidence of an excess of sequences from chromosome 21. These techniques require expensive equipment (sequencer, bioinformatic platform, servers) and a technical time and important analysis (often several days for a single run). Concerning the research of aneuploidies by digital PCR (dPCR), few publications are today due to the absence of sufficiently powerful instruments until recently. DPCR is less expensive.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03687866
Study type	Observational
Source	University Hospital, Caen
Contact
Status	Terminated
Phase
Start date	January 2013
Completion date	December 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02109770` - Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA
Completed	`NCT01925742` - Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood	N/A
Completed	`NCT01852708` - Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
Recruiting	`NCT05527652` - Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia	N/A
Completed	`NCT02278536` - Multiple Gestation Study
Completed	`NCT01511458` - Non-invasive Chromosomal Examination of Trisomy Study	N/A
Not yet recruiting	`NCT05970965` - Periodontitis and Inflammation in Children With Down Syndrome/Trisomy 21: Study on Biological Samples	N/A
Terminated	`NCT03551418` - Learning by Repetitive Viewing of Peer Modeling Patient Education Videos by Adults With Down Syndrome	N/A
Completed	`NCT01966991` - Prenatal Screening for Down Syndrome With DNAFirst	N/A
Enrolling by invitation	`NCT03559374` - Study of Vanadis® NIPT for Non-invasive Prenatal Screening of Trisomies (T21, T18 and T13)
Active, not recruiting	`NCT01725438` - Non Invasive Prenatal Diagnosis of Trisomy 21 by Genetic Analysis of Circulating Fetal Cells	N/A
Active, not recruiting	`NCT05981521` - Paternal Age and Fetal Aneuploidy
Completed	`NCT05004337` - Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies
Recruiting	`NCT02864108` - The Crnic Institute Human Trisome Project Biobank
Completed	`NCT01931644` - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Not yet recruiting	`NCT06200519` - Assessment of Diastolic Function During the Transitional Period and Infancy Using Serial Echocardiography
Terminated	`NCT01545674` - Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial
Terminated	`NCT04747275` - Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients	Phase 4
Completed	`NCT01821300` - Down Syndrome Metabolic Health Study
Completed	`NCT00877292` - A New Prenatal Blood Test for Down Syndrome	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Non-invasive Screening of Fetal Trisomy 21 by Digital PCR — dPNI-T21

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms